ClinConnect ClinConnect Logo
Search / Trial NCT06457126

Piloting the Attention Training Technique for Post-Stroke Emotionalism

Launched by UNIVERSITY OF MANCHESTER · Jun 12, 2024

Trial Information

Current as of August 20, 2025

Not yet recruiting

Keywords

Stroke Post Stroke Emotionalism Attention Training Technique Crying Symptoms

ClinConnect Summary

This clinical trial is focused on testing a new method called the Attention Training Technique (ATT) to see if it can help people who have experienced emotional challenges after a stroke, known as Post Stroke Emotionalism (PSE). PSE can cause uncontrollable crying or emotional outbursts that don't match the situation. The study will involve at least three stroke survivors who are at least six months post-stroke and are receiving support from a community rehabilitation service. Participants will attend weekly appointments for up to 15 weeks, either in person or via video call, and will work with their caregivers to track their emotional symptoms.

To qualify for this trial, participants must be aged 18 or older, have had a confirmed stroke diagnosis, and experience symptoms of PSE. They also need support from a caregiver who can help monitor their progress. Throughout the study, researchers will look at whether the ATT improves emotional symptoms compared to a simpler approach where participants listen to instructions without actively engaging. This trial aims to gather evidence to support a promising new way to help stroke survivors manage their emotional challenges.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Confirmed primary clinical diagnosis of an ischemic or haemorrhagic stroke.
  • At least six months or more post-stroke
  • Reported/observed difficulties with symptoms of PSE (episodes of uncontrollable and unpredictable crying that is not mood congruent and happens in situations that the person would not have otherwise cried)
  • Scores between 6-16 on the Testing Emotionalism after Stroke Questionnaire (TEARS-Q; Broomfield et al., 2021)
  • Scores \> 25 on the Frenchay Aphasia Screening Test (FAST; Enderby, Wood, and Wade 1987).
  • Aged 18 or over.
  • Has the Mental Capacity (Mental Capacity Act, 2005) to provide informed consent.
  • Has carer support and consents to their carer being involved.
  • Proficient in English Language
  • No anticipated changes to antidepressant medication (if applicable).
  • Exclusion Criteria:
  • Less than six months post-stroke
  • Presenting with PSE without a primary diagnosis of an ischemic or haemorrhagic stroke and/or as a result of another neurological condition.
  • Hyper acutely or acutely unwell with concurrent medical conditions.
  • Receiving palliative or end of life care.
  • Severe or distressing behaviours that may impede on engagement or cause further distress.
  • Visual or hearing impairment unable to be corrected.

About University Of Manchester

The University of Manchester is a leading research institution known for its commitment to advancing healthcare through innovative clinical trials. With a strong emphasis on multidisciplinary collaboration, the university leverages its extensive expertise in biomedical research and clinical practice to develop and evaluate new therapies and interventions. The institution is dedicated to improving patient outcomes and public health by conducting rigorous, ethically sound trials that adhere to the highest standards of scientific integrity. Through its state-of-the-art facilities and a robust network of healthcare partnerships, the University of Manchester actively contributes to the global body of medical knowledge and the translation of research findings into clinical applications.

Locations

Manchester, , United Kingdom

Manchester, , United Kingdom

Patients applied

0 patients applied

Trial Officials

Adrian Wells

Study Director

University of Manchester

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported